Dry AMD trial doses first patient
US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD).
US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD).
The trial, to determine safety, tolerability and pharmacokinetics of the oral treatment, is a single-site, double-masked, placebo-controlled, single ascending-dose study treating healthy subjects.
ACU-02 reduces the accumulation of A2E, thereby interrupting the pathophysiology of AMD and preserving retinal cells.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
